Development and Initial Validation of PROMIS GI Distress Scale

PROMIS GI 应激量表的开发和初步验证

基本信息

  • 批准号:
    7944064
  • 负责人:
  • 金额:
    $ 50.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Patient-Reported Outcomes Measurement Information System (PROMIS) initiative aims to develop and disseminate core patient-reported items banks across a wide taxonomy of biopsychosocial illness experiences. Although the current PROMIS taxonomy is expansive, it does not yet include items pertaining to gastrointestinal (Gl) Distress. Our objectives are to first develop a Gl Distress domain using the rigorous standards established by the PROMIS network, and then to test the resulting items in 3 distinct patient populations with Gl distress: (1) irritable bowel syndrome (IBS), (2) inflammatory bowel disease (IBD), and (3) systemic sclerosis (SSc) at 4 large Medical Centers. Our UOl has 2 specific research aims: 1) To develop a Gl Distress item pool by: (a) developing an initial Gl Distress item pool by identifying extant items in the literature, removing redundant and vague items, and revising chosen items to reach uniformity, and (b) expanding the initial pool and establishing content validity by conducting focus groups and cognitive interviews of patients in three patient groups: IBS, IBD, and SSc. 2) To evaluate the psychometric properties of the Gl Distress item pool by: (a) evaluating the dimensionality of the Gl distress item pool and assessing fit of item response theory models in 3 samples of 500 patients with IBS, IBD, and SSc (n=1500 overall), (b) evaluating the associations of the Gl Distress domains with health-related quality of life legacy instruments for Gl illness and with symptom severity, and (c) evaluating the responsiveness and estimating the minimally important differences for the Gl Distress domains. To achieve these aims, we have convened a team of clinicians with expertise in assessing PROs, experts in PRO item development and evaluation, and experts in item response theory. The narrative describes our evolving conceptual framework for Gl Distress, reviews preliminary data from our group regarding PRO measurement in Gl disorders, emphasizes our past experience using PROMIS. PUBLIC HEALTH RELEVANCE: Gl disorders engender an extraordinary burden of illness in the United States. This burden includes the high population prevalence, overwhelming costs of care, and the large impact of Gl disorders on health-related quality of life (HRQOL). Moreover, the Gl-specific rate of health care visits rose by 20 percent between 2000-2004. Given the significant burden of illness of Gl disorders, coupled with the over-representation of many Gl disorders in women, it is vital that the PROMIS taxonomy expand to include items pertaining to Gl Distress.
描述(由申请人提供):患者报告结果测量信息系统(PROMIS)计划旨在开发和传播生物心理社会疾病经历的广泛分类的核心患者报告项目库。尽管当前的 PROMIS 分类范围很广泛,但它尚未包括与胃肠道 (GI) 不适有关的项目。我们的目标是首先使用 PROMIS 网络建立的严格标准开发胃肠道不适领域,然后在 4 个大型医疗中心测试 3 个不同胃肠道不适患者群体的结果项目:(1) 肠易激综合征 (IBS)、(2) 炎症性肠病 (IBD) 和 (3) 系统性硬化症 (SSc)。我们的大学有 2 个具体研究目标:1) 通过以下方式开发胃肠道不适项目库:(a) 通过识别文献中现有的项目、删除冗余和模糊的项目并修改所选项目以达到统一性来开发初始胃肠道困扰项目库,以及 (b) 通过对三个患者组(IBS、IBD 和 SSc)的患者进行焦点小组和认知访谈来扩大初始库并建立内容有效性。 2) 通过以下方式评估 GI 困扰项目池的心理测量特性:(a) 评估 GI 困扰项目池的维数,并评估 500 名 IBS、IBD 和 SSc 患者的 3 个样本(总体 n=1500)中项目反应理论模型的拟合度,(b) 评估 GI 困扰领域与健康相关的 GI 疾病生活质量遗留工具和症状严重程度的关联,以及 (c) 评估 反应性并估计胃肠道应激域的最小重要差异。为了实现这些目标,我们召集了一支由具有评估 PRO 专业知识的临床医生、PRO 项目开发和评估专家以及项目反应理论专家组成的团队。该叙述描述了我们不断发展的胃肠道应激概念框架,回顾了我们小组关于胃肠道疾病 PRO 测量的初步数据,强调了我们过去使用 PROMIS 的经验。公共卫生相关性:胃肠道疾病在美国造成了巨大的疾病负担。这种负担包括高人口患病率、巨大的护理费用以及胃肠道疾病对健康相关生活质量 (HRQOL) 的巨大影响。此外,2000 年至 2004 年间,全球特定医疗保健就诊率上升了 20%。鉴于胃肠道疾病造成的巨大疾病负担,再加上许多胃肠道疾病在女性中的比例过高,因此将 PROMIS 分类法扩展到包括与胃肠道窘迫有关的项目至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DINESH KHANNA其他文献

DINESH KHANNA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DINESH KHANNA', 18)}}的其他基金

Systemic Sclerosis-Associated Interstitial Lung Disease Response Index
系统性硬化症相关间质性肺疾病反应指数
  • 批准号:
    9761276
  • 财政年份:
    2017
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes research in rheumatic diseases
风湿性疾病的结果研究
  • 批准号:
    8348789
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    9526645
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    8713226
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    8917860
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    10254297
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    10001966
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    8532822
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Outcomes Research in Rheumatic Diseases
风湿性疾病的结果研究
  • 批准号:
    9762841
  • 财政年份:
    2012
  • 资助金额:
    $ 50.37万
  • 项目类别:
Development and Initial Validation of PROMIS GI Distress Scale
PROMIS GI 应激量表的开发和初步验证
  • 批准号:
    7780848
  • 财政年份:
    2009
  • 资助金额:
    $ 50.37万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.37万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了